2022 News Release
-
JPMA, PhRMA and EFPIA: Joint Statement on FY2023 NHI Price Revisions
-
JPMA Statement on the TRIPS Waiver Agreement at the 12th WTO Ministerial Conference
-
Statement by Research-based Biopharmaceutical Industry on the Trips Waiver Discussions at WTO Ministerial Conference 12
-
Joint Statement by JPMA PhRMA and EFPIA
-
JPMA Statement on the informal WTO TRIPS Waiver discussions